Co-Authors
This is a "connection" page, showing publications co-authored by Katrien Lagrou and Pieter Vermeersch.
Connection Strength
1.308
-
Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. J Clin Virol. 2021 03; 136:104765.
Score: 0.233
-
Immunoassays for anti-SARS-CoV-2 antibodies: recent insights. Lancet Infect Dis. 2021 05; 21(5):e120.
Score: 0.228
-
Comparison of the diagnostic performance with whole blood and plasma of four rapid antibody tests for SARS-CoV-2. Clin Chem Lab Med. 2020 09 25; 58(10):e197-e199.
Score: 0.226
-
Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect. 2020 Nov; 26(11):1557.e1-1557.e7.
Score: 0.224
-
Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. Clin Microbiol Infect. 2020 Aug; 26(8):1082-1087.
Score: 0.221
-
Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a Phylogenetically Distinct Strain. Clin Infect Dis. 2021 07 15; 73(2):354-356.
Score: 0.060
-
Comparison of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-19 in Symptomatic and Asymptomatic Outpatients. J Clin Microbiol. 2021 06 18; 59(7):e0037421.
Score: 0.059
-
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021 03; 192(6):1100-1105.
Score: 0.057